Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:35:31.972Z.
Calculation as of: 2026-10-06T17:35:31.972Z.
Quote observation: 2026-10-06T17:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: adca945f375d0863f0f013440b023eebfab0caffb47005764e85a23fe93f72ce
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$600.01M
PE Ratio
4.75
TTM Avg
17.55
3Y Avg
51.19
5Y Avg
25.53
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $572.76M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $564.46M | 3.38 | 5.18 | 15.60 | 15.60 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $587.03M | N/A | 419.02 | 415.26 | 415.26 |
| Fulgent Genetics, Inc. (FLGT)vs › | $586.43M | N/A | 4.23 | 40.60 | 40.60 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.76M | N/A | 80.35 | 49.81 | 49.81 |
| AngioDynamics, Inc. (ANGO)vs › | $591.88M | N/A | 43.31 | 43.31 | 89.76 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.01M | 4.75 | 17.55 | 51.19 | 25.53 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $540.81M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $535.61M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.57
Forward EPS (Est.)
$-0.49
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2024-05-07 | 397.65 |
| 2024-05-06 | 411.76 |
| 2024-05-03 | 414.12 |
| 2024-05-02 | 385.88 |
| 2024-05-01 | 396.47 |
| 2024-04-30 | 395.29 |
| 2024-04-29 | 440.00 |
| 2024-04-26 | 478.82 |
| 2024-04-25 | 462.35 |
| 2024-04-24 | 458.82 |
| 2024-04-23 | 503.53 |
| 2024-04-22 | 515.29 |
| 2024-04-19 | 483.53 |
| 2024-04-18 | 529.41 |
| 2024-04-17 | 461.18 |
| 2024-04-16 | 452.94 |
| 2024-04-15 | 463.53 |
| 2024-04-12 | 460.00 |
| 2024-04-11 | 481.18 |
| 2024-04-10 | 478.82 |
| 2024-04-09 | 481.18 |
| 2024-04-08 | 478.82 |
| 2024-04-05 | 482.35 |
| 2024-04-04 | 489.41 |
| 2024-04-03 | 515.29 |
| 2024-04-02 | 487.06 |
| 2024-04-01 | 485.88 |
| 2024-03-28 | 501.18 |
| 2024-03-27 | 482.35 |
| 2024-03-26 | 477.65 |
| 2024-03-25 | 491.76 |
| 2024-03-22 | 515.29 |
| 2024-03-21 | 515.29 |
| 2024-03-20 | 530.59 |
| 2024-03-19 | 628.24 |
| 2024-03-18 | 648.24 |
| 2024-03-15 | 716.47 |
| 2024-03-14 | 617.65 |
| 2024-03-13 | 640.00 |
| 2024-03-12 | 600.00 |
| 2024-03-11 | 581.18 |
| 2024-03-08 | 574.12 |
| 2024-03-07 | 668.24 |
| 2024-03-06 | 591.76 |
